Your browser doesn't support javascript.
loading
Transoral Laser Microsurgery versus Robot-Assisted Surgery for Squamous Cell Carcinoma of the Tongue Base (Oncological and Functional Results)-A Retrospective GETTEC Multicenter Study.
Brudasca, Ioana; Philouze, Pierre; Morinière, Sylvain; Lallemant, Benjamin; Vergez, Sébastien; Malard, Olivier; Roux, Pierre-Eric; Rossello, Noémie; Payen, Caroline; Céruse, Philippe.
Afiliación
  • Brudasca I; Service d'ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Croix Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
  • Philouze P; Service d'ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Croix Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
  • Morinière S; Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Régional Universitaire Bretonneau, 37000 Tours, France.
  • Lallemant B; Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire de Nîmes, 30900 Nîmes, France.
  • Vergez S; Service d'ORL et Chirurgie Cervico-Faciale, Oncopole, Institut Universitaire du Cancer de Toulouse, 31059 Toulouse, France.
  • Malard O; Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire de Nantes, 44093 Nantes, France.
  • Roux PE; Service d'ORL et Chirurgie Cervico-Faciale, Centre Léon Bérard, 69008 Lyon, France.
  • Rossello N; Service d'ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Croix Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
  • Payen C; Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire de Nîmes, 30900 Nîmes, France.
  • Céruse P; Service d'ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Croix Rousse, Hospices Civils de Lyon, 69004 Lyon, France.
J Clin Med ; 12(13)2023 Jun 22.
Article en En | MEDLINE | ID: mdl-37445244
ABSTRACT
The base of the tongue (BOT) is the second most common site for squamous cell carcinoma (SCC) in the oropharynx. There are currently no clear guidelines for the management of BOT SCC. Our main objective was to compare the oncological outcomes of two minimally invasive approaches, transoral laser microsurgery (TLM) and transoral robot-assisted surgery (TORS). This was a retrospective French GETTEC (Groupe d'Études des Tumeurs de la Tête et du Cou) multicenter study of patients with BOT SCC removed surgically either by TLM or TORS between 2005 and 2021. The study group included 16 patients treated by TLM and 38 by TORS, with median follow-up times of 14.4 and 37.2 months, respectively. The overall survival (OS) rates at 2 and 3 years were 67% in the TLM group and 90% at 2 years and 86% at 3 years in the TORS group (p = 0.42, p = 0.20). There was no significant difference in recurrence-free survival (RFS) between the two techniques after 2 and 3 years. The tumors removed by TORS were significantly larger. Operative times were significantly shorter in the TLM group. There were no differences in feeding resumption; none of the patients in the TLM group required a tracheotomy. Postoperative hemorrhagic complication rates were similar in the two groups (12% for TLM and 13% for TORS). Both TORS and TLM showed encouraging oncological, functional, and safety results in BOT SCC even in recurrence or second primary cancer patients, without a technique being found superior in terms of OS or RFS. Tumors removed by TORS were larger without an increase in postoperative bleeding, extending the possibilities of transoral treatment.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Francia